Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
IPO Year: 2014
Exchange: NASDAQ
Website: ardelyx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $10.00 | Buy | H.C. Wainwright |
| 5/2/2025 | $11.00 | Strong Buy → Outperform | Raymond James |
| 3/7/2025 | Buy | Ladenburg Thalmann | |
| 3/4/2025 | $14.00 | Buy | BTIG Research |
| 11/11/2024 | $11.00 → $5.50 | Buy → Neutral | H.C. Wainwright |
| 7/2/2024 | $15.00 → $7.00 | Overweight → Neutral | Piper Sandler |
| 4/5/2024 | $14.00 | Outperform | Leerink Partners |
| 12/18/2023 | $12.00 | Strong Buy | Raymond James |
| 9/7/2023 | $9.00 | Buy | H.C. Wainwright |
| 8/25/2023 | $5.00 → $10.00 | Neutral → Overweight | Cantor Fitzgerald |